Bridgebio
bridgebio.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
BridgeBio is a biotechnology company focused on designing transformative medicines for patients with genetic diseases. It employs a novel approach to drug development by integrating finance with science to deliver solutions as efficiently as possible. The company is committed to developing not only life-changing drugs but also leaders in the field, encouraging hands-on engagement and the pursuit of innovation.
News
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (
Read more
Report
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC ...
Read more
Report
Report
BridgeBio to Participate in May and June Investor Conferences
--BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:. BofA Se
Read more
Report
Pro access
Upgrade to see all 13 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.